Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146906 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT07146906: Recruiting Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT07146906 is a Phase 2 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07146906, a Phase 2 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
Primary Outcome
Change in mesangial IgA deposition as assessed by intensity of immunofluorescence staining
Interventions
- BIOLOGICAL zigakibart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2030-10-18 |
| Phase | Phase 2 |
What NCT07146906 shows while recruiting
NCT07146906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 1 intervention - of which zigakibart is the first listed.
NCT07146906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07146906 about?
NCT07146906 is a clinical study titled "A Study to Assess the Effects of Zigakibart on IgA Nephropathy.". The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
What is the current status of trial NCT07146906?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2026-03-26. Estimated completion is 2030-10-18.
What interventions are being tested in trial NCT07146906?
The interventions under investigation include: zigakibart (BIOLOGICAL).
Who is sponsoring clinical trial NCT07146906?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07146906's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI